TD Cowen analyst Tyler Van Buren has maintained their bullish stance on OLMA stock, giving a Buy rating on April 28.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Tyler Van Buren’s rating is based on Olema Pharmaceuticals’ promising clinical trial results and strategic advancements. The company recently reported impressive Phase II data for its pala+ribo combination, showing a median progression-free survival (mPFS) of over 13 months, which is notably longer than results from comparable trials. This positive outcome suggests a competitive edge in the treatment of ER+/HER2- metastatic breast cancer.
Additionally, Olema is on track to initiate a Phase III trial for the pala+ribo combination in first-line patients, with significant cost savings secured through an agreement with Novartis. The ongoing enrollment for the Phase III monotherapy trial, OPERA-01, further supports the company’s robust pipeline, with data expected in 2026. These factors collectively underpin Van Buren’s Buy rating, reflecting confidence in Olema’s potential for future growth and success in the oncology market.
In another report released on April 28, H.C. Wainwright also reiterated a Buy rating on the stock with a $30.00 price target.